Biodesix マネジメント
マネジメント 基準チェック /24
Biodesixの CEO はScott Huttonで、 Jan2020年に任命され、 の在任期間は 6.33年です。 の年間総報酬は$ 2.24Mで、 28.7%給与と71.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.48%を直接所有しており、その価値は$ 700.78K 。経営陣と取締役会の平均在任期間はそれぞれ6年と6.2年です。
主要情報
Scott Hutton
最高経営責任者
US$2.2m
報酬総額
| CEO給与比率 | 28.74% |
| CEO在任期間 | 6.3yrs |
| CEOの所有権 | 0.5% |
| 経営陣の平均在職期間 | 6yrs |
| 取締役会の平均在任期間 | 6.2yrs |
経営陣の近況
Recent updates
ナラティブの更新 • May 02
BDSX: Improved Balance Sheet And 2026 Revenue Outlook Will Support Upside
Analysts have lifted their price target on Biodesix to $73.88 from $57.08, citing above-expectation 2026 revenue guidance, three consecutive quarters of execution above target, and a "significantly improved" balance sheet that together support a higher assumed future P/E multiple. Analyst Commentary Recent research commentary points to a more constructive view on Biodesix, with bullish analysts highlighting the company’s 2026 revenue guidance, operating execution, and balance sheet as key reasons for a higher valuation framework.
ナラティブの更新 • Apr 16
BDSX: Improved Balance Sheet And 2026 Guidance Will Support Upgraded Rating
Analysts have nudged their price target on Biodesix higher to $30.00 from $30, citing 2026 revenue guidance that is 3% ahead of expectations, a "significantly improved" balance sheet, and three consecutive quarters of execution above target as reasons for a more constructive view. Analyst Commentary Bullish Takeaways Bullish analysts view the upgrade to an Outperform rating as a signal that recent execution and guidance support a higher valuation framework than before.ナラティブの更新 • Apr 01
BDSX: Strong Guidance And Healthier Balance Sheet Will Support 2026 Momentum
Analysts have raised their price target on Biodesix from $30.00 to $56.14, citing 2026 revenue guidance that is 3% above prior expectations and a "significantly improved" balance sheet, with execution running above target for three consecutive quarters. Analyst Commentary Bullish Takeaways Bullish analysts point to the 2026 revenue guidance coming in 3% above prior expectations as support for a higher valuation range, given that it directly feeds into forward revenue estimates and P/S assumptions.
ナラティブの更新 • Mar 18
BDSX: Improved Balance Sheet And 2026 Guidance Will Support Upside
Analysts have maintained their price target on Biodesix, citing 2026 revenue guidance that is 3% ahead of expectations, a "significantly improved" balance sheet, and what they see as three consecutive quarters of above target execution heading into 2026. Analyst Commentary The latest upgrade frames Biodesix as entering 2026 with momentum, supported by revenue guidance that sits 3% ahead of expectations and an improved balance sheet.ナラティブの更新 • Mar 04
BDSX: Improved Balance Sheet And Guidance Will Support Momentum Into 2026
Analysts have reduced their price target on Biodesix from $35 to $30, citing updated fair value assumptions along with views that recent revenue guidance, improving margins, and a lower discount rate better reflect the company’s execution and balance sheet strength. Analyst Commentary Bullish Takeaways Bullish analysts point to the upgrade to an Outperform rating as a sign that recent execution and guidance are more in line with what they view as fair value.ナラティブの更新 • Feb 18
BDSX: Raised 2025 Revenue Guidance Will Support Path To Profitability
Analysts have revised their price target on Biodesix to $40.00 from $40, reflecting updated views on discount rate, revenue growth, profit margin, and future P/E assumptions in their models. What's in the News Biodesix raised its revenue guidance for the fiscal year ending December 31, 2025, estimating total revenue of $88.5 million, above the previously increased range of $84 million to $86 million (company guidance).ナラティブの更新 • Feb 02
BDSX: Raised 2025 Revenue Guidance Will Support Path To Profitability
Analysts have adjusted their price target on Biodesix to US$40.00 from US$40, citing updated assumptions around discount rates, revenue growth, profit margin, and future P/E that collectively refine, rather than overhaul, their previous view. What's in the News Biodesix issued new earnings guidance for the fourth quarter ended December 31, 2025, estimating total revenue of US$28.8 million for the period (Key Developments).ナラティブの更新 • Jan 19
BDSX: Expanded Diagnostics Partnership Will Drive Revenue Upside In 2025
Analysts have increased their price target on Biodesix to reflect updated views on revenue growth potential and a slightly lower discount rate, while also adjusting expected profit margins and future P/E assumptions to align with their latest models. What's in the News Biodesix issued earnings guidance for the fourth quarter of 2025, estimating total revenue of $28.8 million for the period (Corporate guidance).分析記事 • Jan 14
Investors Still Aren't Entirely Convinced By Biodesix, Inc.'s (NASDAQ:BDSX) Revenues Despite 26% Price Jump
Despite an already strong run, Biodesix, Inc. ( NASDAQ:BDSX ) shares have been powering on, with a gain of 26% in the...ナラティブの更新 • Jan 05
BDSX: Expanded Diagnostics Partnership And ESR1 Assay Rollout Will Drive Upside
Analysts have lifted their price target on Biodesix to US$20.00 from US$1.50, citing adjusted assumptions around revenue growth, profit margin, discount rate, and a lower future P/E multiple as the key drivers of this revised view. What's in the News Biodesix raised its fiscal 2025 revenue guidance and now expects total revenue between US$84 million and US$86 million for the year (Key Developments).ナラティブの更新 • Dec 14
BDSX: Reverse Split And ATM Access Will Support Path To Profitability
Analysts have significantly lifted their price target on Biodesix from $2.00 to $40.00, citing updated models following the 20 for 1 reverse split, a reduced share count, and the company’s ability to utilize its at the market facility to support operations through an expected path to cash flow breakeven and profitability. Analyst Commentary Bullish analysts interpret the new price target framework as a constructive signal for Biodesix, emphasizing that the reset reflects mechanical impacts from the 20 for 1 reverse split rather than a fundamental deterioration in the business outlook.分析記事 • Nov 29
Biodesix, Inc.'s (NASDAQ:BDSX) Shares Leap 27% Yet They're Still Not Telling The Full Story
Biodesix, Inc. ( NASDAQ:BDSX ) shareholders are no doubt pleased to see that the share price has bounced 27% in the...分析記事 • Nov 05
US$32.50: That's What Analysts Think Biodesix, Inc. (NASDAQ:BDSX) Is Worth After Its Latest Results
Biodesix, Inc. ( NASDAQ:BDSX ) just released its latest quarterly results and things are looking bullish. Revenues and...分析記事 • Sep 18
It's Down 27% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks
The Biodesix, Inc. ( NASDAQ:BDSX ) share price has softened a substantial 27% over the previous 30 days, handing back...ナラティブの更新 • Sep 16
Digital Integration And Expanded Lung Diagnostics Will Broaden Markets
The substantial increase in Biodesix’s consensus price target is accompanied by a modest improvement in forward earnings valuation and a slight rise in discount rate, indicating more favorable future expectations despite a marginally higher cost of capital, with fair value rising markedly to $35.00. What's in the News Biodesix announced a 1-for-20 stock split.分析記事 • Jul 29
The Market Lifts Biodesix, Inc. (NASDAQ:BDSX) Shares 67% But It Can Do More
Those holding Biodesix, Inc. ( NASDAQ:BDSX ) shares would be relieved that the share price has rebounded 67% in the...分析記事 • Jun 14
Biodesix, Inc. (NASDAQ:BDSX) Stock Rockets 30% But Many Are Still Ignoring The Company
Those holding Biodesix, Inc. ( NASDAQ:BDSX ) shares would be relieved that the share price has rebounded 30% in the...分析記事 • May 15
Analysts Just Slashed Their Biodesix, Inc. (NASDAQ:BDSX) EPS Numbers
The latest analyst coverage could presage a bad day for Biodesix, Inc. ( NASDAQ:BDSX ), with the analysts making...分析記事 • May 14
It's Unlikely That Biodesix, Inc.'s (NASDAQ:BDSX) CEO Will See A Huge Pay Rise This Year
Key Insights Biodesix's Annual General Meeting to take place on 20th of May Salary of US$588.9k is part of CEO Scott...分析記事 • Apr 19
Investors Give Biodesix, Inc. (NASDAQ:BDSX) Shares A 33% Hiding
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 33% in the last...
新しいナラティブ • Apr 03
Sales Force Expansion And CLARIFY Study Will Boost Test Adoption
Expansion of sales force and test adoption, along with CLARIFY study results, are expected to drive revenue growth and improve margins.分析記事 • Mar 05
It's Down 30% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 30% in the last...分析記事 • Jan 19
The Price Is Right For Biodesix, Inc. (NASDAQ:BDSX) Even After Diving 27%
Biodesix, Inc. ( NASDAQ:BDSX ) shareholders that were waiting for something to happen have been dealt a blow with a 27...分析記事 • Nov 21
With A 26% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 26% in the last...分析記事 • Sep 24
Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Jun 12
Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear
When you see that almost half of the companies in the Healthcare industry in the United States have price-to-sales...分析記事 • Mar 03
With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For
The Biodesix, Inc. ( NASDAQ:BDSX ) share price has softened a substantial 25% over the previous 30 days, handing back...分析記事 • Jan 04
Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce
Biodesix, Inc. ( NASDAQ:BDSX ) shareholders are no doubt pleased to see that the share price has bounced 28% in the...分析記事 • Jul 16
It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 28% in the last...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$32m |
| Dec 31 2025 | US$2m | US$643k | -US$35m |
| Sep 30 2025 | n/a | n/a | -US$40m |
| Jun 30 2025 | n/a | n/a | -US$41m |
| Mar 31 2025 | n/a | n/a | -US$40m |
| Dec 31 2024 | US$2m | US$589k | -US$43m |
| Sep 30 2024 | n/a | n/a | -US$44m |
| Jun 30 2024 | n/a | n/a | -US$45m |
| Mar 31 2024 | n/a | n/a | -US$47m |
| Dec 31 2023 | US$2m | US$515k | -US$52m |
| Sep 30 2023 | n/a | n/a | -US$63m |
| Jun 30 2023 | n/a | n/a | -US$66m |
| Mar 31 2023 | n/a | n/a | -US$69m |
| Dec 31 2022 | US$3m | US$515k | -US$65m |
| Sep 30 2022 | n/a | n/a | -US$58m |
| Jun 30 2022 | n/a | n/a | -US$56m |
| Mar 31 2022 | n/a | n/a | -US$52m |
| Dec 31 2021 | US$5m | US$490k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$34m |
| Jun 30 2021 | n/a | n/a | -US$32m |
| Mar 31 2021 | n/a | n/a | -US$29m |
| Dec 31 2020 | US$2m | US$364k | -US$31m |
| Sep 30 2020 | n/a | n/a | -US$33m |
| Jun 30 2020 | n/a | n/a | -US$34m |
| Mar 31 2020 | n/a | n/a | -US$33m |
| Dec 31 2019 | US$337k | US$298k | -US$31m |
報酬と市場: Scottの 総報酬 ($USD 2.24M ) は、 US市場 ($USD 638.05K ) の同規模の企業の平均を上回っています。
報酬と収益: Scottの報酬は増加しましたが、会社は利益を上げていません。
CEO
Scott Hutton (53 yo)
6.3yrs
在職期間
US$2,238,470
報酬
Mr. Scott Hutton serves as President, Chief Executive Officer and Director at Biodesix, Inc. since January 1, 2020. He served as Chief Operating Officer at Biodesix, Inc. since March 2018 until December 20...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 6.3yrs | US$2.24m | 0.48% $ 700.8k | |
| CFO, Secretary & Treasurer | 9.1yrs | US$962.00k | 0.16% $ 233.2k | |
| Chief Commercial Officer | 8.3yrs | US$1.01m | 0.097% $ 141.1k | |
| Founder & CTO | no data | データなし | データなし | |
| Chief Scientific Officer | less than a year | データなし | 0.10% $ 148.9k | |
| Senior Director of Human Resources | 2.3yrs | データなし | データなし | |
| Chief Growth Officer | 6.2yrs | データなし | データなし | |
| Co-Chief Medical Officer | no data | データなし | データなし | |
| Co-Chief Medical Officer | 6yrs | データなし | データなし | |
| Head of Radiomics | 1.3yrs | データなし | データなし | |
| VP & Controller | 5.3yrs | データなし | 0.016% $ 22.8k |
6.0yrs
平均在職期間
50yo
平均年齢
経験豊富な経営陣: BDSXの経営陣は経験豊富で経験豊富です（平均在職期間は6年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 6.3yrs | US$2.24m | 0.48% $ 700.8k | |
| Independent Chairman | 17.9yrs | US$26.87k | 0.25% $ 363.7k | |
| Independent Director | 17.9yrs | データなし | 22.88% $ 33.2m | |
| Independent Director | 5.8yrs | US$31.71k | 0.18% $ 261.2k | |
| Independent Director | 3.3yrs | US$26.87k | 12.59% $ 18.3m | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 14.3yrs | US$30.10k | 1.51% $ 2.2m | |
| Independent Director | 4.4yrs | US$26.87k | 0.18% $ 256.9k | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 6.1yrs | US$33.32k | 0.053% $ 77.7k |
6.2yrs
平均在職期間
62.5yo
平均年齢
経験豊富なボード: BDSXの 取締役会 は 経験豊富 であると考えられます ( 6.2年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/21 17:05 |
| 終値 | 2026/05/21 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Biodesix, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8
| アナリスト | 機関 |
|---|---|
| Sung Ji Nam | BTIG |
| Kyle Mikson | Canaccord Genuity |
| William Bonello | Craig-Hallum Capital Group LLC |